Treatment News : Early Treatment May Do More Harm Than Good in Poor Regions

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 14, 2013

Early Treatment May Do More Harm Than Good in Poor Regions

While U.S. treatment guidelines recommend universal treatment of HIV, the benefits of such a policy may not outweigh the costs in resource-poor areas around the globe. Three researchers from Johns Hopkins University published a paper in Clinical Infectious Diseases, arguing that the limited scope and inconsistent availability of antiretrovirals (ARVs), as well as diminished laboratory monitoring capacity, prompt ethical considerations about applying U.S. treatment standards to impoverished countries at this time.

Recommending early treatment for HIV in the United States is intended both to improve the health outlook of people living with the virus and to curb transmission to others. The increasing clarity of these benefits in recent years has been accompanied by a steady decline in the toxicity of newer ARVs. The Hopkins researchers posit that early use of ARVs in resource-poor settings still clearly benefits prevention efforts as well as people with HIV. However, they argue that because the available ARVs are more antiquated, people beginning therapy with high CD4 counts may put themselves at risk of side effects and toxicity. In addition, less effective therapies and inadequate or non-existent laboratory monitoring may lead people to develop drug resistance, thus potentially limiting future treatment options.

“Universal treatment should be the long-term goal, both for the benefit of those infected and for its effect on slowing and ultimately stopping the epidemic,” the authors write. “But in the enthusiasm for the benefits of ART, we must not lose sight of the glaring disparities among nations that stand as obstacles to the ethical implementation of ART.”

To read the study abstract, click here.

Search: HIV, antiretroviral treatment, universal treatment, resource-poor settings, Clinical Infectious Diseases, Johns Hopkins University.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.